Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
You may also be interested in...
Several South Korean companies are set to present updates on their growing lung cancer pipelines at a major meeting in Chicago this month, underlining the high unmet needs and strong R&D interest in this area by firms in the country.
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.